CSF3R mutations define a distinct high‐risk subset of AML, characterized by reduced remission rates, lower measurable residual disease negativity, and significantly inferior survival—most notably among patients harboring CEBPA basic leucine zipper domain mutations. Here, CSF3R is linked to acute myeloid leukemia.